School of Biomedical Engineering and Sciences, Virginia Tech-Wake Forest University, Blacksburg, VA, USA.
Electrophoresis. 2011 Sep;32(18):2523-9. doi: 10.1002/elps.201100081. Epub 2011 Aug 26.
This work is the first to demonstrate the ability of contactless dielectrophoresis (cDEP) to isolate target cell species from a heterogeneous sample of live cells. Since all cell types have a unique molecular composition, it is expected that their dielectrophoretic (DEP) properties are also unique. cDEP is a technique developed to improve upon traditional and insulator-based DEP devices by replacing embedded metal electrodes with fluid electrode channels positioned alongside desired trapping locations. Through the placement of the fluid electrode channels and the removal of contact between the electrodes and the sample fluid, cDEP mitigates issues associated with sample/electrode contact. MCF10A, MCF7, and MDA-MB-231 human breast cells were used to represent early, intermediate, and late-staged breast cancer, respectively. Trapping frequency responses of each cell type were distinct, with the largest difference between the cells found at 20 and 30 V. MDA-MB-231 cells were successfully isolated from a population containing MCF10A and MCF7 cells at 30 V and 164 kHz. The ability to selectively concentrate cells is the key to development of biological applications using DEP. The isolation of these cells could provide a workbench for clinicians to detect transformed cells at their earliest stage, screen drug therapies prior to patient treatment, increasing the probability of success, and eliminate unsuccessful treatment options.
这项工作首次展示了非接触式介电泳(cDEP)从活细胞的异质样本中分离目标细胞种类的能力。由于所有细胞类型都具有独特的分子组成,因此预计它们的介电泳(DEP)特性也是独特的。cDEP 是一种技术,通过用位于所需捕获位置旁边的流体电极通道代替嵌入式金属电极,来改进传统的基于绝缘体的 DEP 设备。通过放置流体电极通道并消除电极与样品流体之间的接触,cDEP 减轻了与样品/电极接触相关的问题。MCF10A、MCF7 和 MDA-MB-231 人乳腺癌细胞分别代表早期、中期和晚期乳腺癌。每种细胞类型的捕获频率响应都不同,细胞之间的最大差异在 20 和 30 V 之间。在 30 V 和 164 kHz 时,可以成功地从含有 MCF10A 和 MCF7 细胞的群体中分离出 MDA-MB-231 细胞。选择性浓缩细胞的能力是开发使用 DEP 的生物应用的关键。这些细胞的分离可以为临床医生提供一个工作台,以便在最早阶段检测到转化细胞,在对患者进行治疗之前筛选药物治疗方法,从而增加成功的可能性,并消除不成功的治疗选择。